343 related articles for article (PubMed ID: 33212326)
1. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Komrokji R; Steensma D; Balleari E; Götze KS; Kotsianidis I; Guerci-Bresler A; Stamatoullas A; Sanz GF; Germing U; Fenaux P
Leuk Res; 2020 Dec; 99():106472. PubMed ID: 33212326
[No Abstract] [Full Text] [Related]
2. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
[TBL] [Abstract][Full Text] [Related]
3. Novel therapies in low- and high-risk myelodysplastic syndrome.
Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
[No Abstract] [Full Text] [Related]
4. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
Park S; Kelaidi C; Meunier M; Casadevall N; Gerds AT; Platzbecker U
Ann Hematol; 2020 Jan; 99(1):7-19. PubMed ID: 31650290
[TBL] [Abstract][Full Text] [Related]
5. Lowering the boom on lower-risk myelodysplastic syndromes.
Sekeres MA; Patel BJ
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):367-372. PubMed ID: 31808873
[TBL] [Abstract][Full Text] [Related]
6. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
Kang C; Syed YY
Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
[TBL] [Abstract][Full Text] [Related]
7. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
8. How we manage adults with myelodysplastic syndrome.
Fenaux P; Platzbecker U; Ades L
Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
[TBL] [Abstract][Full Text] [Related]
9. Therapy for lower-risk MDS.
Carraway HE; Saygin C
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Garcia-Manero G; Mufti GJ; Fenaux P; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Ilhan O; Sekeres MA; Zeidan AM; Ito R; Zhang J; Rampersad A; Sinsimer D; Backstrom JT; Platzbecker U; Komrokji RS
Blood; 2022 Jan; 139(4):624-629. PubMed ID: 34758066
[No Abstract] [Full Text] [Related]
11. Luspatercept for the treatment of congenital sideroblastic anemia: Two case reports.
Shao Y; He L; Ding S; Fu R
Curr Res Transl Med; 2024 Mar; 72(1):103438. PubMed ID: 38244303
[TBL] [Abstract][Full Text] [Related]
12. Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.
Feld J; Navada SC; Silverman LR
Leuk Res; 2020 Oct; 97():106430. PubMed ID: 32763582
[TBL] [Abstract][Full Text] [Related]
13. β-Thalassemias.
Taher AT; Musallam KM; Cappellini MD
N Engl J Med; 2021 Feb; 384(8):727-743. PubMed ID: 33626255
[No Abstract] [Full Text] [Related]
14. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Molica M; Rossi M
Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
[TBL] [Abstract][Full Text] [Related]
15. Luspatercept: First Approval.
Markham A
Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073
[TBL] [Abstract][Full Text] [Related]
16. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
Mies A; Hermine O; Platzbecker U
Curr Hematol Malig Rep; 2016 Dec; 11(6):416-424. PubMed ID: 27595736
[TBL] [Abstract][Full Text] [Related]
17. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
[TBL] [Abstract][Full Text] [Related]
18. New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat.
Tefferi A
Am J Hematol; 2021 Jul; 96(7):761-763. PubMed ID: 33861878
[No Abstract] [Full Text] [Related]
19. Treatment of Acquired Sideroblastic Anemias.
Mangaonkar AA; Patnaik MM
Hematol Oncol Clin North Am; 2020 Apr; 34(2):401-420. PubMed ID: 32089219
[TBL] [Abstract][Full Text] [Related]
20. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
